Compare Stocks: TSHA, HHH, CGON, and ERAS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$62.40 -1.2%	$73.22	$35.80 ▼ $80.97	$5.53B	0.28	1.09 million shs	1.19 million shs
ERAS Erasca	$14.78 -4.4%	$16.46	$2.11 ▼ $24.28	$5.17B	0.61	5.90 million shs	5.31 million shs
HHH Howard Hughes	$72.58 +0.3%	$66.69	$60.09 ▼ $91.07	$4.33B	1.14	495,468 shs	512,238 shs
TSHA Taysha Gene Therapies	$3.58 -13.5%	$5.46	$3.55 ▼ $7.30	$1.17B	1.19	3.04 million shs	6.12 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-1.08%	-8.12%	-12.74%	-12.04%	+45.97%
ERAS Erasca	-3.56%	+5.03%	-2.64%	-20.72%	+540.17%
HHH Howard Hughes	-1.73%	+0.80%	+17.42%	+0.38%	-7.74%
TSHA Taysha Gene Therapies	-7.80%	-7.80%	-17.53%	-27.37%	-15.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$62.40 -1.2%	$73.22	$35.80 ▼ $80.97	$5.53B	0.28	1.09 million shs	1.19 million shs
ERAS Erasca	$14.78 -4.4%	$16.46	$2.11 ▼ $24.28	$5.17B	0.61	5.90 million shs	5.31 million shs
HHH Howard Hughes	$72.58 +0.3%	$66.69	$60.09 ▼ $91.07	$4.33B	1.14	495,468 shs	512,238 shs
TSHA Taysha Gene Therapies	$3.58 -13.5%	$5.46	$3.55 ▼ $7.30	$1.17B	1.19	3.04 million shs	6.12 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-1.08%	-8.12%	-12.74%	-12.04%	+45.97%
ERAS Erasca	-3.56%	+5.03%	-2.64%	-20.72%	+540.17%
HHH Howard Hughes	-1.73%	+0.80%	+17.42%	+0.38%	-7.74%
TSHA Taysha Gene Therapies	-7.80%	-7.80%	-17.53%	-27.37%	-15.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.70	Moderate Buy	$87.50	40.22% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	49.46% Upside
HHH Howard Hughes	2.25	Hold	$81.00	11.60% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	256.68% Upside

Current Analyst Ratings Breakdown

Latest TSHA, HHH, CGON, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	HHH Howard Hughes	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$100.00 ➝ $83.00
9/21/2026	TSHA Taysha Gene Therapies	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/17/2026	TSHA Taysha Gene Therapies	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
9/14/2026	HHH Howard Hughes	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
9/8/2026	ERAS Erasca	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/14/2026	ERAS Erasca	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/13/2026	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$20.00 ➝ $21.00
8/12/2026	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$18.00 ➝ $22.00
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$82.00 ➝ $85.00
8/7/2026	CGON CG Oncology	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$82.00 ➝ $85.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,369.09	N/A	N/A	$9.33 per share	6.69
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
HHH Howard Hughes	$1.47B	2.94	$6.13 per share	11.84	$64.69 per share	1.12
TSHA Taysha Gene Therapies	$9.77M	119.39	N/A	N/A	$0.90 per share	3.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
HHH Howard Hughes	$123.90M	$4.94	14.69	18.15	N/A	12.31%	7.51%	2.41%	N/A
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest TSHA, HHH, CGON, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	TSHA Taysha Gene Therapies	-$0.1286	N/A	N/A	N/A	$0.76 million	N/A
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	HHH Howard Hughes	$0.49	$2.68	+$2.19	$2.68	N/A	$1.12 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
HHH Howard Hughes	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
ERAS Erasca	N/A	8.29	8.29
HHH Howard Hughes	1.35	2.31	2.31
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
ERAS Erasca	67.78%
HHH Howard Hughes	93.83%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
ERAS Erasca	14.20%
HHH Howard Hughes	47.70%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
HHH Howard Hughes	500	59.72 million	31.23 million	Optionable
TSHA Taysha Gene Therapies	99	325.83 million	314.50 million	Optionable

TSHA, HHH, CGON, and ERAS Headlines

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5% - What's Next?

October 13 at 12:20 PM | marketbeat.com

Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value

October 9, 2026 | finance.yahoo.com

Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?

October 9, 2026 | finance.yahoo.com

Comparing MediWound (NASDAQ:MDWD) and Taysha Gene Therapies (NASDAQ:TSHA)

October 9, 2026 | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Brokerages

October 7, 2026 | americanbankingnews.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock Has Average Target Price of $12.77 According to Brokerages

October 7, 2026 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant under Nasdaq Listing Rule 5635(4)

October 6, 2026 | marketscreener.comM

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.4% - Time to Sell?

October 5, 2026 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 5.4% - Should You Sell?

October 5, 2026 | marketbeat.com

Analyzing Amylyx Pharmaceuticals (NASDAQ:AMLX) and Taysha Gene Therapies (NASDAQ:TSHA)

October 5, 2026 | americanbankingnews.com

Head to Head Analysis: Artiva Biotherapeutics (NASDAQ:ARTV) vs. Taysha Gene Therapies (NASDAQ:TSHA)

October 4, 2026 | americanbankingnews.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

October 4, 2026 | biospace.comB

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026 | globenewswire.com

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

October 1, 2026 | globenewswire.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 5.7% - Here's What Happened

September 28, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

September 11, 2026 | seekingalpha.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, HHH, CGON, and ERAS Company Descriptions

CG Oncology NASDAQ:CGON

$62.40 -0.73 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$62.38 -0.02 (-0.03%)

As of 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Erasca NASDAQ:ERAS

$14.78 -0.68 (-4.40%)

Closing price 04:00 PM Eastern

Extended Trading

$14.65 -0.13 (-0.88%)

As of 07:30 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Howard Hughes NYSE:HHH

$72.58 +0.24 (+0.33%)

Closing price 03:59 PM Eastern

Extended Trading

$72.43 -0.15 (-0.21%)

As of 07:30 PM Eastern

Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.

Taysha Gene Therapies NASDAQ:TSHA

$3.58 -0.56 (-13.53%)

Closing price 04:00 PM Eastern

Extended Trading

$3.62 +0.04 (+1.12%)

As of 07:38 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TSHA, HHH, CGON, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TSHA, HHH, CGON, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TSHA, HHH, CGON, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, HHH, CGON, and ERAS Company Descriptions

CG Oncology NASDAQ:CGON

Erasca NASDAQ:ERAS

Howard Hughes NYSE:HHH

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TSHA, HHH, CGON, and ERAS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TSHA, HHH, CGON, and ERAS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TSHA, HHH, CGON, and ERAS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, HHH, CGON, and ERAS Company Descriptions

CG Oncology NASDAQ:CGON

Erasca NASDAQ:ERAS

Howard Hughes NYSE:HHH

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools